Synovial Sarcoma - Global Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Synovial Sarcoma - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Synovial Sarcoma - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 11, 6 and 8 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Reasons to Buy
Key Topics Covered
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/djof8g
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005306/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
KEYWORD: EUROPE NORTH AMERICA
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 06:06 AM/DISC: 05/28/2019 06:06 AM